<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045382</url>
  </required_header>
  <id_info>
    <org_study_id>TJB0909</org_study_id>
    <nct_id>NCT01045382</nct_id>
  </id_info>
  <brief_title>MSC and HSC Coinfusion in Mismatched Minitransplants</brief_title>
  <official_title>Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims at evaluating the capacity of MSC to improve one-year overall
      survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors
      after non-myeloablative conditioning.

      Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC)
      in an immunodeficient mouse model. In addition, it has been shown that infusion of third
      party MSC in HSC transplantation could be successfully used as treatment for grade II-IV
      steroid-refractory acute graft versus host disease.

      One hundred and twenty patients with HLA-mismatched donors will be included over 6 years at
      multiple centers across Belgium through the transplant committee of the Belgian Hematological
      Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the
      infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or
      not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or
      unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus
      and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of
      the patient will not differ from that of routine NM-HCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year overall survival in the 2 arms.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and grade III-IV acute GVDH</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of absolute donor T cells after HCT in each arm</measure>
    <time_frame>28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extensive chronic GVHD in each arm</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection in each arm.</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality and timing of immunologic reconstitution in each arm.</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with measurable disease at HCT who achieve a complete response in each arm.</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression-free survival</measure>
    <time_frame>365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Leukemia, Myelocytic, Chronic</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Mensenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.
Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.
MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.
Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal stem cell injection</description>
    <arm_group_label>Mensenchymal Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic solution</intervention_name>
    <description>Isotonic solution injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Theoretical indication for a standard allo-transplant, but not feasible because: Age &gt;
             55 yrs. Unacceptable end organ performance. Patient's refusal.

          -  Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months
             after standard autotransplant.

          -  Male or female; fertile female patients must use a reliable contraception method

          -  Age ≤ 75 year old

          -  Informed consent given by patient or his/her guardian if of minor age.

          -  One or two HLA mismatches with PBSC:

               -  One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1

               -  Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1

               -  One antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or
                  -DQB1.

               -  One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B
                  or -C or -DRB1

               -  Patients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
                  can also be included in the protocol.

          -  Hematological malignancies confirmed histologically and not rapidly progressing:

               -  AML in complete remission

               -  ALL in complete remission

               -  CML unresponsive/intolerant to Imatinib but not in blast crisis

               -  Other myeloproliferative disorders not in blast crisis and not with extensive
                  myelofibrosis

               -  MDS with &lt;5% blasts

               -  Multiple myeloma not rapidly progressing

               -  CLL

               -  Non-Hodgkin's lymphoma (aggressive NHL should be chemosensitive)

               -  Hodgkin's disease

        Exclusion Criteria:

          -  Any condition not fulfilling inclusion criteria

          -  HIV positive

          -  Terminal organ failure, except for renal failure (dialysis acceptable)

               -  Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring
                  therapy; ejection fraction &lt;35%; uncontrolled arrhythmia; uncontrolled
                  hypertension

               -  Pulmonary: DLCO &lt; 35% and/or receiving supplementary continuous oxygen

               -  Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal
                  hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding
                  esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic
                  dysfunction evinced by prolongation of the prothrombin time, ascites related to
                  portal hypertension, bacterial or fungal liver abscess, biliary obstruction,
                  chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dL, and symptomatic
                  biliary disease

          -  Uncontrolled infection, arrhythmia or hypertension

          -  Previous radiation therapy precluding the use of 2 Gy TBI

          -  10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Baron, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelyne Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Selleslag, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Brugge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Zachée, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Lewalle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordet Institute, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Bron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordet Institute, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfried Schroyens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Lechanteur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne Baudoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Maertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KUL, Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rik Schots, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ VUB, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augustin Ferrant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL St. LUC, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucien Noens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZG Gent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Doyen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliiques Universitaire Mont-Godinne, Yvoir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tessa Kerre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA, Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Graux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires, Mont-Godinne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <phone>00/32/4 366 7201</phone>
    <email>yves.beguin@chu.ulg.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric Baron, MD, PhD</last_name>
    <phone>00/32/4 366 7201</phone>
    <email>F.Baron@ulg.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edeghem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried Schroyens, MD, PhD</last_name>
      <phone>32 382 204111</phone>
      <email>wilfried.schroyens@uza.be</email>
    </contact>
    <investigator>
      <last_name>Wilfried Schroyens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St-Luc UCL</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Ferrant, MD, PhD</last_name>
      <phone>32 27641880</phone>
      <email>ferrant@sang.ul.ac.be</email>
    </contact>
    <investigator>
      <last_name>Augustin Ferrant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flamish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD</last_name>
      <phone>32- 16 33 22 11</phone>
      <email>johan.maertens@uz.kuleuven.ac.be</email>
    </contact>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Flanders Ost</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <phone>32(09) 332 21 31</phone>
      <email>Lucien.Noens@Ugent.be</email>
    </contact>
    <investigator>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tessa Kerre, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan</name>
      <address>
        <city>Brugge</city>
        <state>Flanders West</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Selleslag, MD</last_name>
      <phone>00/32/50 453060</phone>
      <email>dominik.selleslag@azbrugge.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Graux, MD</last_name>
      <phone>32(081)423831</phone>
      <email>carlos.graux@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Doyen, MD</last_name>
      <phone>32(081)423831</phone>
      <email>chantal.doyen@sang.ucl.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Chantal Doyen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Graux, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Stuyvenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Zachée, MD, PhD</last_name>
      <phone>32(03)2177111</phone>
      <email>pierre.zachee@zna.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Zachée, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Lewalle, MD, PhD</last_name>
      <phone>00/32/2 5417208</phone>
      <email>plewalle@ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Bron, MD, PhD</last_name>
      <phone>00/32/ 2 5417208</phone>
      <email>bron@ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Lewalle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Bron, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Schots, MD</last_name>
      <phone>00/32/2 4763105</phone>
      <email>Rik.Schots@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Rik Schots, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-ULg</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <phone>00/32/4 3667201</phone>
      <email>yves.beguin@chu.ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric Baron, MD, PhD</last_name>
      <phone>00/32/4 3667201</phone>
      <email>F.Baron@chu.ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Baron, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Lechanteur, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Baudoux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne Willems, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>HSC transplantation</keyword>
  <keyword>HLA-mismatched</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>GVHD</keyword>
  <keyword>co-infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

